Exclusive Summary

• Semaglutide patent barriers are diminishing, creating significant global opportunities for generics, especially given the urgent demand in diabetes and obesity.
• Diverse dosage forms cater to various market needs, while potential WHO essential medicines listing solidifies its market position.
• Chinese manufacturing's cost-effectiveness combined with international certifications provides distinct price and quality competitiveness in the global generics market.
• The vast global patient populations for diabetes and obesity are key drivers for the commercial success of generic Semaglutide.
• High market penetrability, offering accessible treatment at affordable prices compared to the high cost of originator drugs.